Radiation Oncology MSK 18-486

A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Breast or Lung Cancer

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

Eligibility Criteria:

  1. Metastatic disease detected on imaging and histologically confirmed:
    1. Triple negative breast cancer (TNBC) (ER <1%, PR <1%, her-2-neu 0- 1+ by IHC or FISH-negative or as determined by MD discretion)
    2. ER+ breast cancer receiving chemotherapy, regardless of HER2 status
    3. Non-small cell lung cancer (NSCLC) without known targetable molecular alterations in EGFR, ALK, or ROS1
    4. NSCLC with EGFR, ALK, or ROS1 targetable molecular alterations who had a history of disease progression on first-line tyrosine kinase inhibitor
  2. If primary disease was previously treated with local therapy in the form of surgery or radiation, any new local/regional disease recurrence should be technically treatable with SBRT or hypofractionated radiation. If the clinical scenario deem that other forms of local therapy may be more suitable for the local/regional recurrent disease, such as surgical resection and interventional radiology-guided ablation, patients would be able to undergo other forms of local therapy with discussion with the PI.

This study is for patients age 18 and older.

Available at: Hartford HealthCare, Hospital of Central Connecticut, Midstate Medical Center, William Backus Hospital.

MSK_ClinicalTrials_Ad